T1	Participants 393 523	Twenty-four patients (twelve of whom were controls) treated with high-dose chemotherapy and autologous bone marrow transplantation
T2	Participants 538 573	The 12 patients treated with GM-CSF
T3	Participants 1178 1240	disease-free survival was 64% for patients treated with GM-CSF
T4	Participants 1245 1311	58% for patients who received placebo after 32 months of follow-up
T5	Participants 1794 1869	patients with relapsed Hodgkin disease who received intensive chemotherapy.
